Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570644 | 0.80 | CYP19A1 (0.48) | TSHRNPSR1LMNAKDM4ECYP2C19 | |
| SCHEMBL3471819 | 0.80 | TSHR (0.48) | TSHRNPSR1LMNAKDM4ECYP2C19 | |
| SCHEMBL13616676 | 0.68 | TSHR (0.43) | TSHRNPSR1LMNAKDM4ECYP2C19 | |
| SCHEMBL12385126 | 0.68 | TSHR (0.54) | TSHRNPSR1LMNAKDM4ECYP2C19 | |
| SCHEMBL3706662 | 0.67 | TSHR (0.58) | TSHRNPSR1LMNAKDM4ECYP2C19 | |
| Ethosuximide SCHEMBL4654769 | 0.66 | TSHR (1.00) | TSHRNPSR1LMNAKDM4ECYP2C19 | |
| Ethosuximide SCHEMBL20980115 | 0.66 | TSHR (1.00) | TSHRNPSR1LMNAKDM4ECYP2C19 | |
| Ethosuximide SCHEMBL118395 | 0.66 | TSHR (1.00) | TSHRNPSR1LMNAKDM4ECYP2C19 | |
| Ethosuximide SCHEMBL34212 | 0.66 | TSHR (1.00) | TSHRNPSR1LMNAKDM4ECYP2C19 | |
| SCHEMBL1322859 | 0.65 | POLB (0.44) | TSHRNPSR1KDM4ECYP19A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389742-B2 | 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20110201807-A1 | 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME | TANAKA DAISUKE | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201807-A1 | 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME | CBR3, TERT, NOX4 | TSHR 511/4885NPSR1 1966/4885LMNA 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.